Cardiovascular Disorders
| Focus: | Cardiovascular Disorders |
|---|---|
| Type: | database (supplied by e-mail as setup.exe file) |
| No. of deals: | 100 |
| No. of companies: | 107 |
| Years covered: | 1996 – 2011 |
| Price: | € 700 ex VAT (if applicable) |
| System requirements: | Windows 2000/Windows XP/Windows Vista / 7 |
| Publisher: | PharmaPlus Consultancy B.V. |
Are you about to enter deal negotiations for your cardiovascular therapeutic?
Use PharmaDeal Financials Cardiovascular Disorders to benchmark your next cardiovascular deal
PharmaDeal Financials Cardiovascular Disorders
- Deal specifics on more than 100 cardiovascular deals
- Deal making trends since 1996
- Deals ranging from leading licensees like Merck & Co and Bristol-Myers Squibb to local licensees like Wanbang Biopharmaceuticals
- All indications and compound classes including antibodies, ion channel modulators, Factor Xa inhibitors, RNA modulators and stem cells
- 44% early stage deals
- Potential deal sizes antisense and stem cell deals by one top licensee up to USD 1.9 billion
- Total milestones for worldwide rights to ion channel modulators from USD 2 to 540 million
- Equity from USD 0.3 million to 220 million
Each deal entry is categorized and searchable by licensor, licensee, indication, compound details, compound name, development stage (research-filed), geographical territory, potential deal size, upfront, total milestones-regulatory milestones-sales milestones payments, profit sharing, royalties on sales, research funding, equity and by year of deal establishment or any combination thereof.
Indications (selection)
Acute cardiovascular disorders, acute coronary syndromes, arrhytmia, atherosclerosis, atrial fibrillation, cholesterol management, coronary artery disease, heart failure, hypertension, myocard infarction, pulmonary arterial hypertension, stroke, thrombosis
Companies included in database
Abbott Laboratories (Kos Pharmaceuticals, Solvay Pharmaceuticals), Actelion (CoTherix), Addrenex Pharmaceuticals, Alexion Pharmaceuticals, Ambrx, Amgen (Tularik), ARCA Biopharma (Nuvelo), Archemix Corporation, ARYX Therapeutics, Asahi Kasei Pharma Corporation, Astellas Pharma (Fujisawa Pharmaceutical Co.), AstraZeneca, AtheroGenics, Avanir Pharmaceuticals, Bayer, Biogen Idec (Biogen), BioInvent International, BioLineRx, BioTime, Boehringer Ingelheim, Bristol-Myers Squibb (Amira Pharmaceuticals, DuPont Pharmaceuticals), Cardiokine, Cardiome Pharma Corporation, Celera Genomics (Axys Pharmaceuticals), Celtic Pharmaceutical Holdings, Cephalon, Cerenis Therapeutics, Chelsea Therapeutics, Cytokinetics, D-Pharm, Daiichi-Sankyo Co. (Sankyo), Dainippon Sumitomo Pharma Co., deCode Genetics, Dendreon Corporation (Corvas International), Dr. Reddy’s Laboratories, ElexoPharm, Eli Lilly & Company, Endo Pharmaceuticals (Indevus Pharmaceuticals/Interneuron Pharmaceuticals), Exelixis, Forest Laboratories, GenVec (Diacrin), Gilead Sciences (CV Therapeutics, Myogen), GlaxoSmithKline (SmithKline Beecham), GTC Biotherapeutics, Heptares Therapeutics, Ikaria, Inflazyme Pharmaceuticals (GlycoDesign), Innogenetics, Isis Pharmaceutials, Intrexon Corporation, Japan Tobacco, Johnson & Johnson (3-Dimensional Pharmaceuticals, Centocor, Scios), Kai Pharmaceuticals, Karo Bio, Kinemed, Leo Pharma, Lexicon Pharmaceuticals (Lexicon Genetics), LifeCycle Pharma, Ligand Pharmaceuticals (CyDex Pharmaceuticals, Pharmacopeia), Lundbeck, MacroGenics, Merck & Co (Schering-Plough/Organon), Merck Serono (Merck KGaA), Mesoblast, Miragen Therapeutics, Mondobiotech, MorphoSys, Neurobiological Technologies, NicOx, Nippon Chemiphar, Nippon Shinyaku, Nissan Chemical Industries, Novartis, Ocinum Biosolutions (Gene Logic), Osiris Therapeutics, Oxford BioMedica, PAION (CeNeS Pharmaceuticals), Pfizer (ICAgen, King Pharmaceuticals, Warner-Lambert, Wyeth/American Home Products), Plexxikon, Portola Pharmaceuticals, Procter & Gamble, PTC Therapeutics, Quark Biotech, Regulus Therapeutics, Roche (Genentech), Sanofi (Genzyme Corporation (GelTex Pharmaceuticals), Rhône-Poulenc Rorer, Sanofi-Aventis), Scion Pharmaceuticals, Seikagaku Corporation, Servier, Shionogi (First Horizon Pharmaceutical, Sciele Pharma), SkyePharma, Synthetic Biologics (Adeona Pharmaceuticals), Taisho Pharmaceutical Co., Takeda Pharmaceutical Company (Millennium Pharmaceuticals, Takeda Chemical), Teijin Pharma, Terumo Corporation, Texas Biotechnology, The Medicines Company, Torrent Pharmaceuticals, UCB Pharma (Schwarz Pharma), Vertex Pharmaceuticals, Vical, Vitae Pharmaceutials, Wanbang Biopharmaceuticals, Xenon Pharmaceuticals, ZymoGenetics
